Tandem Meetings – 2025 – Encore Oral Presentation
Publications
February 15, 2025
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Trem-cel
Presented by: John F. DiPersio, MD, PhD – Washington University School of Medicine Siteman Cancer Center